STAT Plus: Vertex angers U.K. cystic fibrosis patients with a delay in submitting data for its newest therapy

Vertex Pharmaceuticals (VRTX) has sparked a new round of anger among cystic fibrosis patients in the U.K. by requesting extra time to submit evidence for a new triple-combination therapy to a cost-effectiveness agency, a move that will likely delay availability by several months or more.

In explaining its decision, the drug maker said it wants to take advantage of a change the U.K.’s National Institute for Health and Care Excellence is making in its process for assessing the value of medicines, which is expected to be finalized in June 2021. The changes are being made after the agency encountered criticism from both the pharmaceutical industry and patient groups over its approach to deciding value.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Vertex angers U.K. cystic fibrosis patients with a delay in submitting data for its newest therapy »